Bristol Myers Squibb (BMY) to Release Quarterly Earnings on Thursday

Bristol Myers Squibb (NYSE:BMY) is anticipated to release its Q4 2025 results before the market opens on Thursday, February 5th. Analysts expect Bristol Myers Squibb to post earnings of $1.65 per share and revenue of $12.2373 billion for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 5, 2026 at 8:00 AM ET.

Bristol Myers Squibb Stock Performance

NYSE BMY opened at $55.85 on Tuesday. The company has a fifty day moving average price of $53.58 and a 200-day moving average price of $48.72. The firm has a market cap of $113.70 billion, a price-to-earnings ratio of 18.87, a PEG ratio of 0.17 and a beta of 0.29. The company has a debt-to-equity ratio of 2.39, a current ratio of 1.27 and a quick ratio of 1.17. Bristol Myers Squibb has a 1 year low of $42.52 and a 1 year high of $63.33.

Bristol Myers Squibb Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd were given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 4.5%. The ex-dividend date of this dividend was Friday, January 2nd. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s payout ratio is currently 85.14%.

Hedge Funds Weigh In On Bristol Myers Squibb

Several large investors have recently modified their holdings of the business. Brighton Jones LLC boosted its holdings in shares of Bristol Myers Squibb by 33.4% in the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after acquiring an additional 4,935 shares during the period. Sivia Capital Partners LLC raised its stake in shares of Bristol Myers Squibb by 59.4% during the 2nd quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock valued at $346,000 after purchasing an additional 2,786 shares during the period. Caxton Associates LLP purchased a new stake in Bristol Myers Squibb during the 3rd quarter worth about $256,000. Ritter Alpha LP bought a new position in Bristol Myers Squibb in the 3rd quarter worth about $229,000. Finally, DF Dent & Co. Inc. bought a new position in Bristol Myers Squibb in the 3rd quarter worth about $230,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on BMY. Leerink Partners boosted their target price on Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 13th. UBS Group upgraded Bristol Myers Squibb from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $46.00 to $65.00 in a report on Wednesday, January 7th. Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Scotiabank reaffirmed a “sector perform” rating and set a $60.00 target price (up from $53.00) on shares of Bristol Myers Squibb in a research report on Friday, January 9th. Finally, BMO Capital Markets reiterated a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, November 17th. Seven analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $57.43.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.